Correction to: Leukemia advance online publication, 23 September 2010; doi:10.1038/leu.2010.215
Since the publication of this paper, the authors have noticed an error on page 3 of their article. The correct sentence is shown below:
‘In the phase III study of nilotinib versus imatinib as first-line treatment for patients with CP CML, patients receiving imatinib were more likely to experience all-grade peripheral edema, eyelid edema and periorbital edema (14, 13 and 12%, respectively) than patients receiving nilotinib 300 mg twice daily (5, 1 and <1%, respectively) or nilotinib 400 mg twice daily (5, 2 and 1%, respectively).’
The authors apologize for any inconvenience caused.
Additional information
The online version of the original article can be found at 10.1038/leu.2010.215
Rights and permissions
About this article
Cite this article
Jabbour, E., Deininger, M. & Hochhaus, A. Erratum: Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 25, 385 (2011). https://doi.org/10.1038/leu.2010.252
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.252
